Last reviewed · How we verify
Prevnar
Prevnar is a marketed vaccine developed by the Abramson Cancer Center at Penn Medicine, though its primary indication and revenue figures are not specified. The key composition patent for Prevnar is set to expire in 2028, which may currently serve as a barrier to entry for competitors. The lack of detailed competitive landscape and trial results poses a significant risk in assessing the drug's long-term market position and effectiveness.
At a glance
| Generic name | Prevnar |
|---|---|
| Also known as | Pneumococcal 7-Valent Conjugate Vaccine, 13-valent pneumococcal conjugate vaccine |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |